novo nordisk's wegovy reduces cardiovascular risk more than lilly's tirzepatide Eli Lilly and Nordisk are tackling heart health next Wegovy's heart benefits due to
Description
Results Of the 138,397 patients, 57% received neither SGLT2-I nor GLP-1RA, 17% received both, 20% received SGLT2-I only, and 6% received GLP-1RA only
a Google Sheets labeled tracker is included, though some Excel formatting may display slightly differently in Sheets
The development of dual GIPRGLP1R coagonists that bind to either one or the other receptor (sequence-mixed dual agonists) has emerged as an innovative therapeutic strategy for obesity and type 2 diabetes
Bronner's soap
Explore the full paper: #Obesity #Semaglutide #GLP1 #WeightManagement #InsulinResistance #PediatricObesity #Endocrinology
Meanwhile, patients are looking for solutions to any number of conditions with the hope that new treatments can provide more options or, perhaps, better outcomes
